Segall Bryant & Hamill LLC Cuts Stock Holdings in Krystal Biotech, Inc. $KRYS

Segall Bryant & Hamill LLC lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,497 shares of the company’s stock after selling 3,749 shares during the period. Segall Bryant & Hamill LLC’s holdings in Krystal Biotech were worth $20,536,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. UMB Bank n.a. raised its stake in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares in the last quarter. Optimize Financial Inc lifted its holdings in shares of Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC boosted its stake in shares of Krystal Biotech by 0.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock valued at $2,211,000 after buying an additional 41 shares in the last quarter. Regal Investment Advisors LLC boosted its stake in shares of Krystal Biotech by 1.0% in the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after buying an additional 44 shares in the last quarter. Finally, Torray Investment Partners LLC grew its holdings in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after acquiring an additional 47 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on KRYS shares. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Evercore restated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Citigroup upped their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Finally, HC Wainwright raised their price objective on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $360.67.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $341.12 on Friday. Krystal Biotech, Inc. has a 1-year low of $130.50 and a 1-year high of $382.54. The company has a market capitalization of $10.06 billion, a P/E ratio of 45.60 and a beta of 0.50. The business has a 50 day moving average price of $339.70 and a 200 day moving average price of $296.28.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, research analysts expect that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,642 shares of company stock valued at $8,243,923 in the last ninety days. Corporate insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.